Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar*, Ahmad Nanaa, Ehab Atallah, Rory M. Shallis, Sacchi de Camargo Correia Guilherme, Aaron D. Goldberg, Antoine N. Saliba, Anand Patel, Jan P. Bewersdorf, Adam S. DuVall, Danielle Bradshaw, Yasmin Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M. Zeidan, Vamsi Kota, Mark R. Litzow

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

11 Scopus citations

Abstract

(Figure presented.)

Original languageEnglish (US)
Article number32
JournalBlood cancer journal
Volume14
Issue number1
DOIs
StatePublished - Dec 2024

Funding

Research reported in this publication from Memorial Sloan Kettering Cancer Center (MSKCC) supported by the NCI of the National Institutes of Health under Award Number P30 CA016359 and P01 CA23766, and Cancer Center Support Grant/Core Grant to MSKCC (P30 CA008748). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Portion of this work was accepted at the American Society of Hematology 2023 and published (PMID: 36807649) [15 ]. Research reported in this publication from Memorial Sloan Kettering Cancer Center (MSKCC) supported by the NCI of the National Institutes of Health under Award Number P30 CA016359 and P01 CA23766, and Cancer Center Support Grant/Core Grant to MSKCC (P30 CA008748). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Portion of this work was accepted at the American Society of Hematology 2023 and published (PMID: 36807649) [].

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)'. Together they form a unique fingerprint.

Cite this